FDA grants breakthrough designation to CytotronJanuary 6, 2020
The Center for Devices and Radiological Health (CDRH) of the US FDA has granted ‘Breakthrough Device Designation’ for the Cytotron, a whole body therapeutic medical device.
The Cytotron is intended to be used to cause degeneration of uncontrolled growth of tissues. It is indicated for treating protein-linked, abnormally regenerating disorders such as neoplastic disease, by selectively targeting and enabling tissue apoptosis, allowing extended progression-free survival, with pain relief, palliation, improved quality and dignity of life. It is indicated for the treatment of solid tumours of the breast, liver, and pancreas.
Cytotron uses RFQMR technology which utilizes radio or sub-radio frequency, low power, non-ionizing, non-thermal electromagnetic waves.
The main concern of the therapy is not the immediate destruction of the cancer cells, but rather with the help of the small amount of energy provided to the cell to stop the DNA’s uncontrolled mitosis, put the cell in a vegetative state and in time through apoptosis mechanism let the body get rid of the cancerous cells in a controlled fashion.
Cytotron is developed by Centre for Advanced Research and Development (CARD) – a division of Scalene Cybernetics Limited in Bengaluru, India.